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Cystic fibrosis is the most common genetically determined, life-limiting disorder in populations of European ancestry.
The genetic basis of cystic fibrosis is well established to be mutations in the cystic fibrosis transmembrane conductance
regulator (CFTR) gene that codes for an apical membrane chloride channel principally expressed by epithelial cells.
Conventional approaches to cystic fibrosis care involve a heavy daily burden of supportive treatments to combat lung
infection, help clear airway secretions and maintain nutritional status. In 2012, a new era of precision medicine in cystic
fibrosis therapeutics began with the licensing of a small molecule, ivacaftor, which successfully targets the underlying
defect and improves CFTR function in a subgroup of patients in a genotype-specific manner. Here, we review the three
main targeted approaches that have been adopted to improve CFTR function: potentiators, which recover the function
of CFTR at the apical surface of epithelial cells that is disrupted in class III and IV genetic mutations; correctors, which
improve intracellular processing of CFTR, increasing surface expression, in class II mutations; and production correctors
or read-through agents, which promote transcription of CFTR in class I mutations. The further development of such
approaches offers great promise for future therapeutic strategies in cystic fibrosis.Targeted therapies in respiratory medicine— cystic
fibrosis as a paradigm
Targeted therapies have evolved in medicine following ad-
vances in molecular technology and the successful map-
ping of the human genome. Such treatments are well
recognized in oncology, where molecules required for
tumor growth and spread are specifically targeted to stop
the malignant process or prevent tumor progression [1, 2].
These therapies have been driven by the concepts of
precision and stratified medicine, whereby molecular bio-
markers can be used to select specific approaches for indi-
viduals or groups of individuals, respectively, enabling the
production of highly effective and precise treatments [3].
Some of the advantages of targeted therapies include the
ability to identify treatment responders, tailor treatment to
an individual’s genetic profile, and avoid unwanted side ef-
fects [4]. This approach is in direct contrast to most drugs
currently used in medical practice, which are used to treat
large populations with the same broad disease label but
with marked heterogeneity in response to treatment.* Correspondence: malcolm.brodlie@ncl.ac.uk
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and an increased understanding of the genetic basis of
complex diseases have enabled the concept of targeted
therapies to be investigated in other areas, such as re-
spiratory medicine. However, there are few examples of
targeted therapies in this field outside of oncological prob-
lems, as most lung diseases are complex and polygenic.
Therefore, developing strategies for specific molecular ab-
normalities in these conditions is challenging. An excep-
tion, however, is cystic fibrosis, in which the underlying
genetic defect is well defined and lies within the CFTR
gene [5]. The use of ivacaftor, a potentiator of CFTR func-
tion, has become a successful reality since 2012 as a tar-
geted therapy for patients with cystic fibrosis caused by
specific genotypes, and represents a powerful example of
precision medicine [6]. Furthermore, the combination of a
potentiator and a corrector (ivacaftor and lumacaftor) re-
ceived US Food and Drug Administration (FDA) approval
in 2015 for use in people with cystic fibrosis caused by the
most common CFTR mutation, Phe508del [7, 8].
In this review we discuss the clinical and genetic basis
of cystic fibrosis, the development of treatments targeted
at specific classes of CFTR mutation to address the basic
defects and improve CFTR function, and the advent ofis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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other respiratory diseases.
Genetic causes, clinical manifestations and patient
care
Cystic fibrosis is the most common autosomal recessive
life-limiting disorder [9]. It is particularly prevalent in
northwestern European populations, with an incidence of
around 1 in 2500 individuals, but it occurs in all popula-
tions worldwide. The CFTR gene was cloned 26 years ago
and it encodes a chloride channel that is primarily
expressed in epithelial cells [5]. Almost 2000 disease-
causing mutations have been identified in people with
cystic fibrosis to date, but a much smaller number of mu-
tations account for the vast majority of cases [9, 10]. CFTR
mutations may be classified into six different categoriesFig. 1 The different classes of CFTR gene mutations and the mechanisms o
lumacaftor) and production correctors (such as ataluren). CFTR gene mutat
result in an absence or reduced quantity of CFTR protein at the cel membr
activity of CFTR at the cell membrane. Potentiators increase the function o
example, ivacaftor increases the probability of Gly551Asp-CFTR channel op
mutant CFTR protein, allowing more to reach the cell surface; for example,
agents) promote the read-through of premature termination codons in mR
in class I CFTR mutationsbased on the mechanisms that are affected: CFTR synthe-
sis, trafficking or function (Fig. 1 and Table 1).
Class I mutations result from nonsense, frameshift, or
mRNA splicing mutations leading to absent CFTR produc-
tion; for example, Gly542X, a nonsense mutation caused by
a premature termination codon (PTC), results in an early
translational defect and a truncated CFTR protein. Class II
mutations, including Phe508del, are caused by defective
CFTR processing. Although CFTR is correctly synthesized,
missense and in-frame deletion mutations disrupt CFTR
folding and trafficking to the cell surface. Class III muta-
tions result in expression of CFTR at the cell membrane
but channel gating is defective and results in impaired
chloride transport function. For example, Gly551Asp, the
most common class III mutation, eliminates the ability of
ATP to increase the opening rate of CFTR [11].f action of CFTR potentiators (such as ivacaftor), correctors (such as
ions are categorized into six classes. Mutation classes I, II, V and VI
ane, whereas mutation classes III and IV influence the function or
f CFTR channels expressed at the apical surface of epithelial cells; for
ening. Correctors improve the intracellular processing and delivery of
lumacaftor in Phe508del-CFTR. Production correctors (read-through
NA, generating more production of CFTR protein; for example, ataluren
Table 1 Summary of different classes of CFTR mutations
Mutation class Nature of defect Functional consequence Example Therapeutic strategy
I CFTR protein synthesis Reduced CFTR protein expression Gly542X Production correctors (ataluren)
II CFTR protein processing Misfolded CFTR not transported to
cell surface
Phe508del Corrector plus potentiator (lumacaftor
plus ivacaftor, VX-661 plus ivacaftor)
III CFTR channel gating Reduced/lack of CFTR channel
opening
Gly551Asp Potentiator (ivacaftor)
IV CFTR channel conductance Misshaped CFTR pore restricts
Cl− movement
Arg117His Potentiator (ivacaftor)
V Reduced CFTR protein production Very low levels of CFTR protein 3849 + 10 kb
C→ T
No data available
VI High CFTR protein turnover at cell
surface
Functional but unstable CFTR protein
at cell surface
120del23 No data available
kb kilobases
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which chloride transport is restricted owing to an abnormal
CFTR channel pore. Class IV mutations, such as
Arg117His, often result in a milder phenotype owing to
partial CFTR function. Very low levels of CFTR are found
in class V mutations, in which splicing defects lead to de-
fective mRNA processing. Finally, class VI mutations are
characterized by a functional but unstable CFTR, resulting
in high CFTR turnover at the cell surface. To add further
complexity to this classification system, certain muta-
tions may lead to more than one class of functional de-
fect, for example, Phe508del results in class II and III
problems [12, 13]. Phe508del-CFTR is degraded at the level
of the endoplasmic reticulum, with very little or zero mu-
tant protein reaching the apical membrane of epithelial
cells, which is typical of a class II CFTR mutation [14]. If
Phe508del-CFTR is expressed at the apical membrane —
for example, following monotherapy with a CFTR corrector
such as lumacaftor — it has been demonstrated that the
chloride channel has a reduced probability of being open,
operating as a class III gating CFTR mutation [15, 16].
Cystic fibrosis is a multi-system disorder, but the vast
majority of morbidity and mortality is associated with
lung disease [9]. Lung disease in cystic fibrosis is charac-
terized by neutrophilic inflammation, retention of mu-
coid secretions and chronic endobronchial infection
with specific organisms, most notably Pseudomonas aer-
uginosa. Ultimately, this leads to progressive bronchiec-
tasis and premature death in young adulthood. Other
clinical problems in cystic fibrosis include malabsorption
due to exocrine pancreatic insufficiency, diabetes and
liver disease. The exact mechanism as to how a defective
chloride channel causes such extensive lung problems is
not fully understood and several hypotheses have been
proposed. These include effects on the airway surface li-
quid (ASL; the thin layer of liquid that sits above the ap-
ical membrane of airway epithelial cells in which cilia
beat) [17], compromised mucociliary clearance [18],alterations in ASL pH [19], defective innate immunity
against pathogens [19], and pro-inflammatory responses
in airway epithelial cells [20–22].
The development and implementation of various symp-
tomatic treatments since cystic fibrosis was first recognized
has greatly improved survival. In the 1970s and 1980s pan-
creatic enzyme replacement therapy and improved nutri-
tional management were introduced [23]. In terms of lung
disease, removal of mucus and secretions with chest
physiotherapy [24] and more advanced lung clearance
devices and techniques, along with the more recent use of
inhaled drugs such as dornase alpha (which helps cleave
DNA in the airway from necrotic neutrophils, reducing the
tenacity of secretions) [25] and hypertonic saline (which
works osmotically by increasing the hydration of mucus
and ASL), have also been beneficial [26]. Furthermore, anti-
microbial therapies targeting acute and chronic infection in
the form of oral, intravenous and inhaled drugs are critical
parts of modern cystic fibrosis treatment [27]. The develop-
ment of specialist centers delivering expert multidisciplin-
ary care in a coordinated fashion has also been crucial in
improving outcomes [28]. At present, the median life ex-
pectancy of patients with cystic fibrosis has increased to
nearly 40 years, with projected survival for newborn infants
with cystic fibrosis born today beyond the fifth decade of
life [29]. Genetic testing is a normal part of the diagnostic
process, along with measurement of sweat chloride levels
as a measure of CFTR function [30].
The treatments described above are all aimed at man-
aging the downstream consequences of defective CFTR
function and improving symptoms rather than tackling
the underlying defect. Furthermore, these therapies rep-
resent a significant burden of care, involving physiother-
apy multiple times a day along with numerous tablets
and nebulizers. This burden is a particular problem in a
lifelong condition such as cystic fibrosis, and adherence
to treatment is a challenge even for the most dedicated
of individuals [31].
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potential therapeutic target
The relationship between the severity of disease in an in-
dividual and sweat chloride concentration as a readout
of the level of CFTR function is complex. However, pa-
tients with mutations associated with lower levels of sweat
chloride — for example, in the intermediate range — gen-
erally have improved survival, slower decline in lung func-
tion and a less severe overall phenotype [32]. This clinical
observation confirms the logic of targeting CFTR to treat
the fundamental defect in cystic fibrosis and makes it a
highly attractive strategy [5].
Gene therapy to introduce the wild-type CFTR gene
into airway epithelial cells in patients with cystic fibrosis
so that they express functional CFTR has an obvious and
elegant rationale. A large amount of careful and method-
ical research has been performed in this field over several
decades [33]. The UK Cystic Fibrosis Gene Therapy Con-
sortium recently published the results of a phase IIb trial
of CFTR gene therapy delivered monthly for a year by
nebulizer using a non-viral liposomal vector [34]. This has
provided proof-of-concept that liposomal CFTR gene
therapy is well tolerated and can provide clinical benefit in
terms of lung function to patients with a broad range of
CFTR genotypes. Interestingly, responses to gene therapy
appeared to be heterogeneous and a greater treatment ef-
fect was observed in participants with lower baseline
forced expiratory volume in one second (FEV1). It is very
likely that further human studies will follow in the next
few years to optimize dosing and to determine in which
patient groups this approach might be most useful [34]. In
the future, gene editing or correction in stem cells may be-
come another genetic approach for cystic fibrosis therapy,
a strategy that was recently demonstrated in 2013 in an
ex vivo intestinal organoid model [35].
An alternative method to address the fundamental
defect in cystic fibrosis is the development of genotype-
specific small-molecule drugs that modulate CFTR func-
tion. Three main approaches have been adopted (Fig. 1).
First, potentiators increase the function of CFTR channels
expressed at the apical surface of epithelial cells and are
used in class III or IV CFTR mutations, in which CFTR
reaches the surface of cells but is dysfunctional. Second,
correctors improve the intracellular processing and deliv-
ery of mutant CFTR protein in class II CFTR mutations,
allowing more protein to reach the cell surface. Last, pro-
duction correctors or read-through agents promote the
read-through of PTCs in mRNA, allowing more produc-
tion of the CFTR protein in class I CFTR mutations.
The simplest and most successful approach to date
has been using small molecules to potentiate CFTR
function in specific class III gating mutations in which
CFTR is present at the cell membrane but is dysfunctional
(Tables 1 and 2 and Fig. 1). The most frequently occurringclass III mutation is Gly551Asp, which accounts for
around 5 % of all mutant CFTR alleles in the population
[11]. Gly551Asp is a missense mutation, in which the
amino acid glycine is substituted for aspartate at position
551 in the nucleotide-binding domain-1 of the gene. Al-
though the protein is present at the cell surface, the chan-
nel fails to open in response to ATP, resulting in defective
chloride channel transport. A CFTR potentiator — such
as ivacaftor — that specifically targets this gating mutation
can increase CFTR function at the cell surface and in
intracellular organelles [36].
Importantly, the most common CFTR mutation by far
is Phe508del, which is found on at least one chromo-
some in around 85 % of people with cystic fibrosis, and
correcting the function of Phe508del-CFTR is much more
challenging [14, 37]. The mutant Phe508del-CFTR protein
is misfolded, which leads to intracellular degradation by
the proteasome in the endoplasmic reticulum, with very
little protein reaching the plasma membrane (class II mu-
tation) [38]. However, in vitro cell culture work has dem-
onstrated that if the temperature of cells is lowered or if
they are treated pharmacologically, it is possible to bypass
the degradation of Phe508del-CFTR and increase traffick-
ing to the plasma membrane [39]. Once expressed at the
membrane, Phe508del-CFTR then behaves as a gating
(class III) mutation whose function could be potentiated in
a similar fashion to Gly551Asp-CFTR [15, 16, 40]. There-
fore, a dual CFTR corrector and potentiator approach is
likely to be required to improve CFTR function in patients
with the Phe508del mutation.
The CFTR potentiatior ivacaftor
Ivacaftor (VX-770) is a small-molecule drug that was iden-
tified via high-throughput screening involving a library of
nearly 230,000 potential therapeutic compounds [41]. Fur-
ther in vitro evaluation demonstrated that ivacaftor signifi-
cantly augmented chloride transport and increased ASL
height and cilia beat frequency in airway epithelial cells ex-
pressing Gly551Asp-CFTR mutation (Fig. 2) [36]. This
watershed moment in cystic fibrosis therapeutics then led
to fast-tracked clinical trials to investigate the efficacy of
ivacaftor as an orally bioavailable drug in patients who had
at least one Gly551Asp allele.
Clinical trials of ivacaftor in patients with the Gly551Asp
CFTR mutation
A phase II double-blinded placebo-controlled trial was
performed to determine the safety, efficacy and adverse
outcomes of different doses of ivacaftor and to ascertain
any clinical improvements with treatment versus placebo
(Table 2) [42]. Biomarkers of CFTR function, lung func-
tion and quality of life measures were also assessed [42].
Measures of CFTR function included nasal potential
difference (as a marker of chloride conductance in the
Table 2 Summary of clinical studies investigating the efficacy of ivacaftor in patients with cystic fibrosis and the Gly551Asp
mutation
Study name and
reference
Accurso et al.
2010 [42]
STRIVE: Ramsey
et al. 2011 [6]
ENVISION: Davies
et al. 2013 [43]
Davies et al.
2013 [44]
Barry et al. 2014 [45]
Type of study Phase II RCT Phase III RCT Phase III RCT Phase III RCT Case–control study
Number of
participants
n = 39 n = 161 n = 52 n = 21 n = 56
Ivacaftor: 31;
placebo: 8
Ivacaftor: 83;
placebo: 78
Ivacaftor: 26;
placebo: 22
Ivacaftor: 21; placebo: 35
Duration 28 days 48 weeks 48 weeks 29 days 9 months
Inclusion criteria ≥18 years ≥12 years 6–11 years ≥6 years ≥18 years
≥1 Gly551Asp allele ≥1 Gly551Asp
allele
≥1 Gly551AspP
allele
≥1 Gly551Asp
allele
≥1 Gly551Asp allele
FEV1 > 40 % FEV1 40–90 % FEV1 40–105 % FEV1 > 90 % FEV1 < 40 %
Weight ≥15 kg LCI >7.4 and/or actively listed
for lung transplant
Weight
≥15 kg
Outcome measure Median change from
baseline with 150 mg
Treatment
effect
Treatment effect Treatment
effect
Changes within
treated patients
Treated patients
versus controls
Mean FEV1
(percentage predicted)
+8.7 (P = 0.008) 24 weeks: +10.6
(P < 0.001)
24 weeks: +12.5
(P < 0.001)
– +4.2 (P = 0.0068) +3.8 versus 0.6
(P = 0.009; median)
48 weeks: +10.5
(P < 0.001)
48 weeks: +10
(P < 0.0006)
Sweat chloride
levels (mmol/L)
−59.5 (P = 0.008) −47.9 (P < 0.001) −54.3 (P < 0.001) – – –
CFQ-R score (points) +8.3 (P = 0.06) +8.6 (P < 0.001) +6.1 (P = 0.109) – – –
Nasal potential
difference (mV)
−3.5 (P = 0.02) – – – – –
Weight (kg) – +2.7 (P < 0.001) +2.8 (P < 0.001) – +1.8 (P = 0.0058;
median)
+2.3 versus 0.6
(P = 0.25; median)
BMI – – BMI-for-age z-score:
0.45 (P < 0.001)
– +1.1 kg/m2 (P = 0.010;
median)
+0.84 versus 0.2 kg/m2
(P = 0.234; median)
Time on intravenous
antibiotics (days per
year)
– – – – −36 (P = 0.0016;
median)
−36 versus +10
(P = 0.0003; median)
Pulmonary
exacerbations
– 55 % risk
reduction
No significant
difference
– – –
(0.455 hazard
ratio: P = 0.001)
LCI – – – −2.16
(P < 0.0001)
– –
BMI body mass index (the weight in kilograms divided by the square of the height in meters), CFQ-R revised Cystic Fibrosis Questionnaire, FEV1 percentage
predicted forced expiratory volume in 1 second for age, sex and height, LCI lung clearance index, RCT randomized controlled trial
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readout of chloride reabsorption by CFTR in the sweat
duct). Lung function was measured in terms of percent-
age of predicted FEV1. Quality of life was assessed using
the revised Cystic Fibrosis Questionnaire (CFQ-R). Pa-
tients aged 18 years or older who had at least one
Gly551Asp allele and a predicted FEV1 of at least 40 %
were included in the study. The first stage of the study
had a crossover design in which patients were randomly
assigned to receive varying doses of ivacaftor (25 mg,75 mg, 150 mg or placebo) every 12 hours over two 14-
day periods with a washout time between these periods.
The second stage was a parallel study, which involved new
patients who were randomly assigned to receive varying
doses of ivacaftor (150 mg, 250 mg or placebo) every
12 hours over 28 consecutive days.
Of 39 patients, 31 (79 %) received ivacaftor and 8 (21 %)
received the placebo. In general, ivacaftor was well toler-
ated. The study found a partial improvement in nasal po-
tential difference and significant improvements in sweat
Fig. 2 Summary of initial in vitro data on effects of ivacaftor (VX-770) on human bronchial epithelial cells (HBEs) expressing the Gly551Asp CFTR
mutation. a Potentiation of CFTR-mediated chloride (Cl−) secretion following treatment with ivacaftor. Chamber techniques were used to record
the transepithelial current (IT) resulting from CFTR-mediated Cl
− secretion. To isolate the CFTR-mediated IT, a basolateral-to-apical Cl
− gradient was
established, 30 μM amiloride was added to block the epithelial sodium channel (ENaC), and 10 μM (maximal effective concentration; EC99) forskolin (FSK)
was applied to activate the CFTR. The concentration–response curve for ivacaftor in the presence of FSK is shown for Gly551Asp/Phe508del HBEs isolated
from the bronchi of a single individual (filled circles; n = 16) and Phe508del HBEs isolated from the bronchi of the three individuals who
responded to ivacaftor (open circles; n= 7–24). Left y-axis shows IT responses; right y-axis shows IT normalized to the 10 μM FSK-stimulated IT in non-cystic
fibrosis (CF) HBEs (mean ± standard error of the mean). Note that the error bars for the Phe508del HBEs were smaller than the symbol. b Increased airway
surface liquid (ASL) following treatment with ivacaftor. Mean (n = 3–9) ASL volume in the absence (open bars) or presence (filled bars) of
10 μM ivacaftor and in the presence of 30 nM vasoactive intestinal peptide (VIP) and/or 20 μM CFTR inhibitor-172 (inh-172). c Increased
ciliary beat frequency (CBF) following treatment with ivacaftor. Mean (± standard error of the mean; n = 6) CBF for wild-type HBEs (filled bars) or
Gly551Asp/Phe508del HBEs (open bars) after a 5-day treatment with DMSO, 30 nM VIP, 10 μM ivacaftor, or 30 nM VIP with 10 μM ivacaftor. Single asterisk
indicates significantly different (P< 0.05) from vehicle control in Gly551Asp/Phe508del HBEs; double asterisk indicates significantly different (P < 0.05) from
vehicle control and ivacaftor alone. EC50 half-maximum effective concentration. Reproduced with permission from Van Goor et al. [36]
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caftor. The median reduction in sweat chloride levels after
28 days in the 150 mg ivacaftor group was −59.5 mmol/L
versus a gain of 5 mmol/L in the placebo group. Interest-
ingly, although still significant, the reduction in sweat
chloride levels was smaller in those who received 250 mg
than in those who received 150 mg of the drug. There
were no significant improvements in FEV1 in patients who
received ivacaftor versus placebo. However, there were
significant within-subject improvements in FEV1 from
baseline with the 75 mg and 150 mg doses. Health-related
quality of life was better with ivacaftor, but the changes
were not significant. Although this study clearly demon-
strated the benefits of ivacaftor in patients with cystic fi-
brosis, it was limited by its small sample size, which may
have contributed towards the lack of significance found
with some outcome measures.
Two larger phase III double-blinded randomized con-
trolled trials (RCTs) were then performed to evaluate the
efficacy of ivacaftor in patients with the Gly551Asp CFTR
mutation (Table 2) [6, 43]. Participants in both studies
were randomly assigned in a 1:1 fashion to receive either150 mg of ivacaftor every 12 hours or placebo during a
48-week period. The STRIVE study was carried out in pa-
tients aged 12 years and over, and the ENVISION study
looked at younger children aged 6–11 years. The primary
outcome of both studies was percentage predicted FEV1
at 24 weeks, with secondary outcomes including FEV1 at
48 weeks, weight, sweat chloride levels, CFQ-R symptom
score and safety profile. In the STRIVE study, time to first
pulmonary exacerbation was also a secondary endpoint.
Both studies demonstrated a significant improvement
in lung function with ivacaftor. In STRIVE, the effect of
treatment on percentage predicted FEV1 at 24 weeks
was 10.6 percentage points (P < 0.001) and at 48 weeks was
10.5 percentage points (P < 0.001) [6]. In the ENVISION
study this effect was 12.5 percentage points (P < 0.0001)
and 10 percentage points (P < 0.0006) at 24 and 48 weeks,
respectively [43]. In both studies, significant improvements
were noted as early as 15 days. In STRIVE, a 55 % risk re-
duction of pulmonary exacerbations was observed with iva-
caftor therapy versus placebo at 48 weeks [6]. This effect
was not seen in the ENVISION study, which was not pow-
ered to detect such a change; the number of pulmonary
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(three events) and the ivacaftor (four events) groups [43].
This can be explained by the younger age and relatively
milder disease seen in ENVISION participants compared
to STRIVE, with mean baseline FEV1 values at 63 % and
84 % predicted, respectively.
In the STRIVE study, the time spent in hospital was
significantly reduced in patients taking ivacaftor. Mean
duration of hospitalization per patient was 3.9 days
(±13.6) in ivacaftor patients versus 4.2 days (±8.7) in the
placebo group. Ivacaftor also reduced the number of ex-
acerbations requiring intravenous treatment by 26 % and
hospitalization by 15 % [6].
These studies clearly demonstrated significant improve-
ments in sweat chloride levels at 24 and 48 weeks. In
STRIVE there was a reduction in sweat chloride levels of
48.7 mmol/L at 24 weeks compared with 0.8 mmol/L
in the placebo group (treatment effect −47.9 mmol/
L, P < 0.001) [6]. Interestingly, the mean sweat chlor-
ide concentrations at this stage were 47.8 mmol/L in the
ivacaftor group versus 100 mmol/L in the placebo group.
The rapid reduction in sweat chloride levels was also seen
in the ENVISION study (treatment effect 54.3 mmol/
L, P < 0.001) [43]. Reductions were sustained at 48 weeks
in both studies.
Improvements in respiratory symptoms were seen in
individuals taking ivacaftor in both studies. The CFQ-R
score was significantly improved in the older patients
(treatment effect of 8.6 points, P < 0.001) [6]. Although
there was an improvement in patients taking ivacaftor in
the ENVISION trial, the findings were not significant
(treatment effect of 6.1 points, P = 0.109) [43]. Baseline
CFQ-R was higher in younger patients, which suggests
that they had relatively milder disease and symptoms.
Parents and caregivers also completed a version of the
CFQ-R, which, interestingly, did reveal significant
improvements. This discrepancy perhaps reflects the
challenges faced when completing and interpreting
health-related questionnaires in children. Patients tak-
ing ivacaftor in both studies showed promising im-
provements in weight gain. At 48 weeks, the effect of
treatment was 2.7 kg in STRIVE (P < 0.001) and 2.8 kg
(P < 0.001) in ENVISION [6, 43].
The most common adverse symptoms were headache,
nasal congestion, upper respiratory tract infection, rash
and dizziness. These effects were similar in the ivacaftor
and placebo groups and all participants were able to con-
tinue treatment [6, 43]. In general, there were fewer serious
adverse events in people taking ivacaftor in both studies
compared with those receiving placebo. These events
included pulmonary exacerbations, productive cough,
hemoptysis and hypoglycemia. One patient receiving iva-
caftor in STRIVE discontinued treatment owing to raised
hepatic enzyme levels [6]. This effect was not seen inENVISION, and in both studies there were no clinically
relevant abnormal laboratory results or physical examin-
ation findings attributable to ivacaftor [6, 43].
In a subsequent phase II crossover study involving pa-
tients aged over 6 years with mild impairment of lung
function, treatment with ivacaftor for 28 days was asso-
ciated with improvements in lung clearance index com-
pared with placebo (Table 2) [44]. Lung clearance index
is measured using multiple-breath washout and is a sen-
sitive method to assess changes in lung function in pa-
tients with cystic fibrosis for whom spirometry is in the
normal range [44].
The effects of ivacaftor have also been studied in pa-
tients with severe impairment of lung function with an
FEV1 percent predicted to be ≤40 % (Table 2) [45]. Sig-
nificant improvements in lung function, number of days
of intravenous antibiotic therapy, weight and body mass
index (BMI) were found among patients after treatment in
a retrospective case–control study [45]. In particular, re-
ductions in treatment requirements — for example, num-
ber of inpatient days for intravenous antibiotics (median
days per year reduced from 23 to 0, P = 0.001) — were felt
to be clinically significant and greater than in studies in-
volving patients with less severe lung disease [45].
In summary, the studies described above have clearly
shown that ivacaftor is associated with significant health
improvements in patients with the Gly551Asp CFTR
mutation, who account for 5 % of people with cystic fi-
brosis, and have highlighted the beneficial role of this
drug as a targeted therapy [46].
Clinical trials of ivacaftor in patients with other CFTR
mutations
Gating mutations other than Gly551Asp account for
around 1 % of all CFTR mutations; individually, many of
these mutations are rare. In addition to Gly551Asp, there
is also in vitro evidence that ivacaftor potentiates CFTR
function in other class III CFTR mutations [36, 47].
Furthermore, ivacaftor also potentiates CFTR function
in vitro in cells expressing CFTR with some residual
function (class IV CFTR mutations) [48]. These muta-
tions include the Arg117His CFTR missense mutation
that causes mixed conductance (class IV) and gating
(class III) abnormalities, which is responsible for
around 2 % of CFTR mutations in northern European
populations [49]. It was hypothesized, therefore, that
ivacaftor might be of potential benefit to people with
cystic fibrosis with other class III and IV mutations,
and clinical studies were undertaken to investigate its
clinical efficacy in those scenarios (Table 3).
As mentioned earlier, the Phe508del CFTR mutation is
much more common and is present in around 85 % of
people with cystic fibrosis. The biology of the Phe508del-
CFTR protein poses a much greater challenge to improve
Table 3 Summary of clinical studies investigating the efficacy of ivacaftor in patients with cystic fibrosis mutations other than
Gly551Asp
Study name and reference Flume et al. 2012 [54] KONNECTION: De Boeck et al. 2014 [51] KONDUCT: Moss et al. 2015 [53]
Type of study Phase II RCT with open
label extension
Phase III randomized crossover
trial with open label extension
Phase III RCT
Number of participants n = 104 n = 39 n = 69
Ivacaftor 34; placebo 35
Duration 16 weeks (96-week
extension)
24 weeks (total) 24 weeks
8 weeks placebo/ivacaftor
8 weeks ivacaftor/placebo
12 weeks ivacaftor
Inclusion criteria ≥12 years ≥6 years ≥6 years
Phe508del homozygous >1 non-Gly551Asp gating mutation >1 Arg117His mutation
FEV1 > 40 % FEV1 > 40 % FEV1 > 40–90 % (>12 years)
FEV1 > 40–105 % (6–11 years)
Weight >15 kg
Outcome measure Treatment effect Treatment effect after 8 weeks Treatment effect
Mean FEV1 (percentage predicted) +1.7 (P = 0.15) +10.7 (P < 0.0001) All ages: +2.1 (P = 0.2)
>18 years: +5 (P = 0.01)
6–11 years: −6.3 (P = 0.03)
Sweat chloride
levels (mmol/L)
−2.9 (P = 0.04) −49.2 (P < 0.0001) −24 (P < 0.0001)
CFQ-R score (points) No significant
differences
+9.6 (P = 0.0004) +8.4 (P = 0.009)
Weight (kg) No significant
differences
– –
BMI No significant differences BMI-for-age z-score 0.28 (P = 0.001) –
BMI body mass index (the weight in kilograms divided by the square of the height in meters), CFQ-R revised Cystic Fibrosis Questionnaire, FEV1 percentage
predicted forced expiratory volume in 1 second for age, sex and height, RCT randomized controlled trial
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defective Phe508del-CFTR protein has a limited response
to CFTR potentiation [50], indicating that ivacaftor could
also potentially benefit patients with this mutation type.
This hypothesis was also tested in clinical studies, de-
scribed in detail below.
Non-Gly551Asp CFTR gating mutations
The KONNECTION study was a two-part randomized
international multicenter study designed to investigate
the safety and efficacy of ivacaftor in patients with cystic
fibrosis over the age of 6 years with a non-Gly551Asp
CFTR gating mutation (Table 3) [51]. Part 1 was an 8-
week blinded placebo-controlled crossover study with a
4–8-week washout period, and part 2 was an open-label
extension period of 24 weeks. The primary outcome of
each part of the study was percentage predicted FEV1,
with secondary outcomes including BMI, sweat chloride
levels and quality of life assessed with the respiratory do-
main of the CFQ-R. There was a statistically significant
increase in FEV1 of 7.5 percentage points in the ivacaftor
group in part 1 and 13.5 percentage points in part 2.BMI and sweat chloride levels decreased and quality of
life improved with ivacaftor therapy in each part of the
study. Subgroup analysis confirmed these findings for in-
dividual genotypes, with the exception of patients with
the Gly970Arg mutation, in which there was a substan-
tially less pronounced reduction in sweat chloride levels.
As in the Gly551Asp studies, ivacaftor was generally well
tolerated, with similar adverse events in the placebo and
treatment groups [51].
Arg117His CFTR mutation
The phenotype associated with the Arg117His mutation is
variable, depending on the other CFTR mutation present
and the presence of a polypyrimidine variant in the intron
8 acceptor splice site; the mutation is often associated with
less severe clinical problems [52].
The KONDUCT study was a phase III randomized
controlled 24-week trial of ivacaftor versus placebo in
people aged ≥6 years with an Arg117His CFTR mutation
(Table 3) [53]. The primary outcome was change in per-
centage predicted FEV1, with secondary outcomes in-
cluding changes in BMI, sweat chloride levels and the
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of 69 patients were recruited in this multicenter study.
The primary outcome was not statistically significant,
with an increase in FEV1 in the treatment group of 2.1 per-
centage points compared with placebo (P = 0.2). Secondary
outcome differences in CFQ-R scores (+8.4, P = 0.009) and
sweat chloride levels (−24 mmol/L, P < 0.001) were statisti-
cally significant. The change in BMI in the treatment group
was not statistically significant (+0.26 kg/m2, P = 0.78). No
new safety concerns were identified [53].
A pre-specified subgroup analysis for the participants
aged over 18 years (n = 50), who had a substantially lower
average baseline percentage predicted FEV1 of around
65 % compared with around 95 % in those aged less than
18 years, showed a statistically significant increase in the
primary outcome of FEV1 (+5 percentage points, P = 0.01)
in the treatment group. Subgroup analysis of the partici-
pants aged less than 18 years, who had a higher baseline
FEV1 of 95.8 %, showed an actual decline in lung function
in the treatment group (−6.3 percentage points, P = 0.03).
An open-label extension study was performed after wash-
out for 65 of the original trial participants. Pooled results
of the extension study showed an improvement in percent-
age predicted FEV1 of +5.1 percentage points at week 12
compared with post-washout baseline values (P < 0.0001)
[53]. Overall, these results suggest a potential benefit of
ivacaftor in patients with the Arg117His CFTR mutation
and more advanced lung disease.
Phe508del CFTR mutation
A phase II study was performed in patients who were
homozygous for Phe508del [54]. A total of 140 clinically
stable patients aged ≥12 years were randomized in a
blinded fashion to receive ivacaftor or placebo for 16 weeks,
which was followed by an open-label extension period for
patients who had demonstrated a pre-specified clinical re-
sponse in the first part of the study. The primary efficacy
outcome was change in percentage predicted FEV1 in the
randomized part of the study, with safety also assessed,
along with secondary outcomes including sweat chloride
concentration, weight and CFQ-R scores.
There was no statistically significant increase in per-
centage predicted FEV1 in the treatment group versus
the placebo group in the first part of the study (+1.7 per-
centage points, P = 0.15), with a very small reduction in
sweat chloride levels (−2.9 mmol/L, P = 0.04). These
changes were not sustained in the open-label phase. The
safety profile of ivacaftor was similar to that of placebo
with no new concerns raised. The conclusion of this
study was that ivacaftor as a CFTR potentiator alone is
not an effective therapeutic strategy for patients with
cystic fibrosis who are homozygous for the Phe508del
mutation [54]. This finding is perhaps not surprising
owing to the very low or no expression of Phe508del-CFTR at the apical surface of epithelial cells in this pa-
tient group (Fig. 1 and Table 1) [55].
Clinical use of ivacaftor in the post-approval setting
Ivacaftor was designated as an orphan medicine by the
European Union in 2008, and since 2012 has been
commissioned for use in the United Kingdom in patients
aged 6 years or older with at least one Gly551Asp allele. It
is also prescribed in most of the rest of Europe, the United
States and other countries with well-developed clinical ser-
vices for cystic fibrosis. Ivacaftor is an expensive drug and,
for example, in the United Kingdom it is currently available
under a Patient Access Scheme as a means to improve the
cost effectiveness of treatment. Although such mutations
are individually rare, in 2014 the European Union granted
approval to ivacaftor for the treatment of people with one
of eight other non-Gly551Asp gating CFTR mutations. In
December 2014 the US FDA also approved the use of iva-
caftor in patients with the Arg117His CFTR mutation.
Whether ivacaftor has definitive long-term benefits re-
mains uncertain but preliminary data seem promising.
Patients from the ENVISION and STRIVE studies were
rolled over to an extended study to investigate the bene-
fits of ivacaftor over a total period of 144 weeks, called
PERSIST (Table 2) [56]. Both groups showed a sustained
improvement in absolute percentage of predicted FEV1
and weight [56]. Furthermore, participants who received
placebo in the original studies responded in a similar fash-
ion to those who received ivacaftor originally [56]. During
the extended study, the adverse event rate remained simi-
lar to previously and no new safety concerns were identi-
fied [56]. Improvements in lung function and nutrition
have also been demonstrated in the post-approval setting
in people with advanced cystic fibrosis-related lung dis-
ease [45, 57, 58].
Despite the exciting and groundbreaking benefits asso-
ciated with ivacaftor, over 90 % of patients with cystic fi-
brosis will not benefit from monotherapy with this
agent. Developing approaches that are targeted at other
common CFTR mutations is therefore a clear priority.
Other CFTR-targeted therapeutic approaches
Ataluren (PTC124) as a production corrector or
read-through agent
Ataluren is an orally bioavailable agent that has been
trialed for use in class I CFTR mutations, which affect
around 10 % of patients with cystic fibrosis [59]. These
so-called ‘nonsense’ mutations involve a PTC. The PTC
results in the interruption of ribosomal translation, result-
ing in a shortened, unstable and non-functional CFTR
protein [60, 61]. Thought to be similar in function to ami-
noglycosides, ataluren enables ribosomes to skip this PTC,
acting as a production corrector or ‘read-through agent’,
leading to the formation of functional protein (Fig. 1). The
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lenged, however, and the drug has been demonstrated to
have some off-target effects on a reporter assay using fire-
fly luciferase activity in drug development [62]. Ataluren
has also been trialed in Duchenne muscular dystrophy
caused by nonsense mutations and has been granted con-
ditional marketing authorization for this indication in the
European Union [63].
A phase II prospective clinical trial of ataluren was
performed in adult patients with cystic fibrosis and a
class I CFTR mutation; the trial included 23 partici-
pants in the first cycle and 21 in the second (Table 4)
[64]. Each cycle varied in the dose of ataluren usedTable 4 Summary of clinical studies investigating the efficacy of ata
Study name and reference Kerem et al. 2008 [64] Sermet-Gaudelu
2010 [46]
Type of study Phase II randomized
crossover trial
Phase II random
crossover trial
Number of participants n = 23 n = 30
Duration Cycle 1: 16 mg/kg/day for
14 days; no treatment for
14 days
2 × 28 days
Cycle 2: 40 mg/kg/day for
14 days; no treatment for
14 days
Cycle 1: 16 mg/
14 days; no trea
14 daysCycle 2:
kg/day for 14 d
treatment for 14
Inclusion criteria ≥18 years 6–18 years
2 disease mutations, >1
nonsense
2 disease mutat
>1 nonsense
Sweat chloride
>40 mmol/L
Sweat chloride
>40 mmol/L
Abnormal nasal
potential difference
Abnormal nasal
potential differe
FEV1 > 40 % FEV1 > 40 %
O2 saturation ≥92 %
room air
O2 saturation ≥
room air
Weight ≥25 kg
Outcome measure Treatment effect Treatment effec
Mean FEV1 (percentage
predicted)
Small increase (P = 0.037) No significant d
Sweat chloride levels (mmol/L) No significant difference –
Chloride transport Cycle 1: −7.1 (P < 0.0001) Cycle 1: −4.6 m
(P = 0.037)
Cycle 2: −3.7 (P = 0.032) Cycle 2: −3.9 m
(P = 0.046)
Nasal potential difference (mV) (Change in basal nasal
potential difference)
–
Cycle 1: +3.3 (P = 0.04)
Cycle 2: +3.1 (P = 0.13)
Weight (kg) +0.6 kg (P < 0.0001) No significant d
Pulmonary exacerbations – –
FEV1 percentage predicted forced expiratory volume in 1 second for age, sex and hbut involved 14 days of treatment, with assessment
of CFTR-mediated chloride transport by measure-
ments of the transepithelial nasal potential differ-
ence. There was no placebo group. Oral treatment
with ataluren was associated with an improvement in
electrophysiological profile in the majority of pa-
tients. In 13 patients in cycle 1 and 9 patients in
cycle 2, total chloride transport entered the normal
range. Ataluren was generally well tolerated by the study
participants. A further 19 patients entered a follow-on
study, in which they received varying doses of ataluren for
another 12 weeks. The results of this study showed on-
going improvement in CFTR function as assessed byluren in patients with nonsense cystic fibrosis mutations
s et al. Wilschanski et al. 2011 [65] Kerem et al.
2014 [66]
ized Extension of trial by Kerem
et al. 2008 [45]
Phase III RCT
n = 19 n = 238
12 weeks 48 weeks
kg/day for
tment for
40 mg/
ays; no
days
Group 1: 16 mg/kg/dayGroup 2 :
40 mg/kg/day
≥18 years ≥6 years
ions, 2 disease mutations,
>1 nonsense
Nonsense
mutations
Sweat chloride >40 mmol/L Sweat chloride
>40 mmol/L
nce
Abnormal nasal
potential difference
Abnormal nasal
potential difference
FEV1 > 40 % FEV1 40–90 %
92 % O2 saturation ≥92 % room air O2 saturation
≥92 % room air
Weight ≥16 kg
t Treatment effect Treatment effect
ifference No significant difference +3 % (P = 0.12)
– –
V Group 1: −6.8 (P < 0.004) –
V Group 2: −3.4 (P = 0.025)
– –
ifference – –
– Rate ratio 0.77
(P = 0.0992)
eight, RCT randomized controlled trial
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new safety issues [65].
Another study of ataluren was performed in children
and young people with cystic fibrosis aged between 6 and
18 years with a class I CFTR mutation [59]. Similar to the
adult study described above, there were two 14-day cycles
of oral treatment, with varying doses in each cycle, and
the primary outcome was nasal potential difference. In
around half of the participants an electrophysiological re-
sponse was demonstrated with ataluren treatment and the
agent was generally well tolerated. Evidence was also dem-
onstrated of increased CFTR expression by nasal epithelial
cells after treatment [59].
These results led to a phase III RCT, the results of which
were published in 2014 [66]. In this study, 238 patients
were recruited and randomized to receive placebo or atalu-
ren for 48 weeks. The primary outcome was change in per-
centage predicted FEV1, with the number of pulmonary
exacerbations as a secondary outcome. There was no statis-
tically significant difference between ataluren treatment
and placebo for the primary outcome (−2.5 versus −5.5 per-
centage points for FEV1, P = 0.12). The secondary outcome
was also not statistically significantly different between
groups. A post hoc analysis was performed in patients
not taking inhaled tobramycin regularly. The analysis
showed that this group had a significant increase in FEV1
of around 5 % with ataluren treatment compared with pla-
cebo (−0.7 % versus −6.4 %, P = 0.0082), along with a re-
duction in the number of pulmonary exacerbations [66].
The authors concluded that the drug may be of benefit to
those not receiving inhaled tobramycin treatment, but it
should be noted that, to date, no phase III trial of ataluren
in cystic fibrosis has met its endpoints [66]. It has been hy-
pothesized that tobramycin interferes with the mechanism
of action of ataluren [66], and a further phase III study is
underway to investigate the efficacy of ataluren in patients
not receiving this antibiotic (ClinicalTrials.gov identifier
NCT02139306) [67].
The CFTR corrector lumacaftor
Lumacaftor (VX-809) is an example of a CFTR corrector.
In vitro studies have shown that lumacaftor improves CFTR
processing and chloride secretion in bronchial epithelial
cells derived from people with cystic fibrosis homozygous
for Phe508del [40]. A subsequent RCT investigated the
safety and effect on CFTR function of lumacaftor mono-
therapy in Phe508del homozygotes [68]. This trial was a
randomized placebo-controlled study involving treatment
with varying doses of the drug for 28 days. The primary
endpoints were the safety and tolerability of lumacaftor,
with secondary outcomes including measures of CFTR
function (sweat chloride levels and nasal potential differ-
ence), percentage predicted FEV1 and CFQ-R score. Treat-
ment with lumacaftor had a similar safety and adverseevent profile to treatment with placebo and no major safety
concerns were raised. Modest but statistically significant
dose-dependent improvements in sweat chloride levels
were demonstrated with lumacaftor treatment. No changes
with lumacaftor were demonstrated in participants who
underwent nasal potential difference measurements.
The study failed to find any significant improvements
in lung function or CFQ-R outcomes associated with
the drug. However, the study was not powered for these
endpoints, and the authors comment that longer and
larger trials would be required to assess these end-
points adequately [68].
Combination therapies
As discussed earlier, the biology associated with the most
common CFTR mutation, Phe508del, is particularly com-
plex, leading principally to both class II and III defects
[12, 14, 15]. This provides an explanation for the disap-
pointing results associated with lumacaftor monotherapy
in patients who are homozygous for the mutation [68] —
if Phe508del-CFTR is expressed at the apical membrane,
the chloride channel still has a (reduced) probability of be-
ing open [15, 39]. To add a further layer of complexity,
Phe508del-CFTR also demonstrates reduced surface sta-
bility if it reaches the apical membrane [13].
Lumacaftor and ivacaftor
Conceptually, the combination of lumacaftor, to correct
intracellular processing of CFTR, with ivacaftor, to po-
tentiate the function of CFTR once it is trafficked to the
plasma membrane, is highly attractive for patients with
the Phe508del CFTR mutation [69].
The results of a complex phase II RCT investigating the
effects of varying doses of lumacaftor in combination with
ivacaftor versus placebo in adult Phe508del patients were
published in 2014 (Table 5) [70]. The trial involved three
successive cohorts of participants, with the results of earlier
cohorts informing optimal dosing of lumacaftor for subse-
quent ones. The first cohort consisted of 64 Phe508del
homozygous patients, and the second and third cohorts in-
cluded 96 homozygotes and 28 compound heterozygotes.
The primary outcomes were change in sweat chloride
levels and safety, with secondary outcomes including per-
centage predicted FEV1. A modest yet statistically signifi-
cant reduction in sweat chloride levels was demonstrated
in treatment groups compared with placebo groups, as well
as an increase of 5.6 percentage points in predicted FEV1
in the highest lumacaftor dose group. There was no signifi-
cant change in FEV1 in the compound heterozygous sub-
group. The frequency and nature of adverse events were
similar between treatment and placebo groups, with no
new concerns raised during the study.
The results from this phase II study were sufficiently
strong to support two phase III RCTs being undertaken in
Table 5 Summary of clinical studies investigating the efficacy of
lumacaftor and ivacaftor in patients with Phe508del mutations
Study name and
reference
Boyle et al. 2014 [70] TRAFFIC and TRANSPORT:
Wainwright et al. 2015 [8]
Type of study Phase II RCT Phase III RCT
Number of
participants and
study design
Cohort 1: Cohort 1:
64 homozygotes n = 368
Lumacaftor 200 mg/day
for 14 days
Lumacaftor 600 mg/day
plus ivacaftor 250 mg
every 12 h
Followed by: Cohort 2:
Ivacaftor 150 mg/250 mg
every 12 h for 7 days
n = 369
OR Lumacaftor 400 mg every
12 h plus ivacaftor
250 mg every 12 h
Placebo for 21 days Cohort 3:
Cohorts 2 and 3: n = 371
96 homozygotes Placabo plus placebo
28 compound
heterozygotes
Cohort 2:
Lumacaftor 200 mg,
400 mg, 600 mg/day for
56 days
Cohort 3:
Lumacaftor 400 mg every
12 h for 56 days
Followed by:
Ivacaftor 250 mg every
12 h after 28 days
OR
Placebo for 56 days
Duration Cohort 1: 21 days 24 weeks
Cohorts 2 and 3: 56 days
Inclusion criteria ≥18 years ≥12 years
>1 Phe508del allele Phe508del homozygous
FEV1 > 40 % FEV1 40–90 %
Outcome
measure
Treatment effect Pooled analysis of
treatment effect in
TRAFFIC and TRANSORT
Mean FEV1
(percentage
predicted)
Cohort 2 with lumacaftor
600 mg/day: +5.6
(P = 0.013)
Cohort 1: +3.3 (P < 0.001)
Cohort 3: no significant
differences
Cohort 2: +2.8 (P < 0.001)
Sweat chloride
levels (mmol/L)
Cohort 1 with 250 mg
ivacaftor: −9.1 mmol/L
(P < 0.001)Cohorts 2 and 3:
no significant differences
–
CFQ-R score
(points)
– Cohort 1: 3.1 (P = 0.007)
Cohort 2: 2.2 (P = 0.05)
BMI – Cohort 1: 0.28 (P < 0.001)
Table 5 Summary of clinical studies investigating the efficacy of
lumacaftor and ivacaftor in patients with Phe508del mutations
(Continued)
Cohort 2: 0.24 (P < 0.001)
Pulmonary
exacerbations
– Cohort 1: rate ratio 0.7
(P = 0.001)
Cohort 2: rate ratio 0.61
(P < 0.001)
BMI body mass index (the weight in kilograms divided by the square of the
height in meters), CFQ-R revised Cystic Fibrosis Questionnaire, FEV1 percentage
predicted forced expiratory volume in 1 second for age, sex and height, RCT
randomized controlled trial
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and safety of lumacaftor/ivacaftor combination therapy
(TRAFFIC and TRANSPORT) [8]. The results of these
studies were published in May 2015 [8]. Each study was
randomized, double-blinded and placebo-controlled, and
recruited patients aged ≥12 years who were homozygous
for Phe508del. Participants were randomized to receive
placebo or one of two different lumacaftor doses (400 mg
twice daily or 600 mg once daily) and ivacaftor (250 mg
twice daily). The primary outcomes were absolute change
from baseline in percentage predicted FEV1, with second-
ary endpoints including relative change in percentage pre-
dicted FEV1, BMI, rate of pulmonary exacerbations and
CFQ-R scores. Both TRAFFIC and TRANSPORT were
large (559 and 563 patients recruited, respectively), multi-
center studies that involved 24 weeks of treatment. The
average baseline lung function of patients was around
60 % predicted FEV1.
There was a statistically significant increase in predicted
FEV1 of between 2.6 and 4 percentage points in the treat-
ment groups compared with placebo groups (P < 0.001).
This difference was maintained in subgroup analyses strati-
fied by age, percentage predicted FEV1 and P. aeruginosa
infection status. In pooled analyses including data from
both studies, the rate of pulmonary exacerbations was
around a third lower in the treatment groups and BMI in-
creased by approximately 1 % [8]. In terms of CFQ-R, a
significant improvement in pooled analyses was only ob-
served for the 600 mg once-daily lumacaftor treatment
group. Seven patients in the treatment group experienced
serious adverse events relating to deranged liver function,
which were normalized with discontinuation of the study
drug. Otherwise, safety profiles were similar among pla-
cebo and treatment groups. There was an increased rate
of discontinuation of the study owing to an adverse event
in the treatment group (4.2 %) compared with the placebo
group (1.6 %). Each of the dosing regimens of lumacaftor
seemed to have similar efficacy, with the exception of pul-
monary exacerbation outcomes, which were more favor-
able in the 400 mg twice-daily lumacaftor group. The
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these studies than in the large Gly551Asp ivacaftor trial,
but is comparable to the improvements demonstrated
with other interventions in cystic fibrosis [6, 25, 71].
It is important to note that in vitro studies published in
2014 have suggested that treatment with ivacaftor over a
longer period actually destabilizes the Phe508del-CFTR
protein that is corrected by treatment with lumacaftor
[72, 73]. These observations may partly explain the mod-
est clinical improvements seen in the phase III TRAFFIC
and TRANSPORT RCTs and highlight the importance of
longer-term studies and awareness of drug–drug interac-
tions involving novel compounds in chronic medical con-
ditions for which polypharmacy is already the norm [8].
VX-661 and ivacaftor
VX-661 is another orally administered CFTR corrector
small-molecule drug [74]. In vitro, VX-661 has been re-
ported to improve trafficking and processing of Phe508del-
CFTR and to have an additive effect when administered
with ivacaftor on chloride transport compared with ivacaf-
tor alone in cells heterozygous for Phe508del/Gly551Asp
CFTR mutations [75]. The preliminary results of a complex
phase II study investigating the safety and tolerability of
VX-661 monotherapy and in combination with ivacaftor in
patients who are homozygous for Phe508del and heterozy-
gous for Phe508del/Gly551Asp CFTR mutations were
presented at the 2014 North American Cystic Fibrosis
Conference [75]. The primary outcome was safety and
change in sweat chloride levels after 28 days of treat-
ment. The study was blinded, randomized and placebo-
controlled, and involved different dosing regimens.
The preliminary results suggest a modest decrease in
sweat chloride levels with VX-661/ivacaftor combination
treatment in Phe508del homozygous patients, with a
dose-dependent increase in FEV1 in the treatment group
compared with the placebo group that was statistically
significant in the two highest dose groups (+4.8 percent-
age points predicted, P = 0.01). In Phe508del/Gly551Asp
heterozygote participants, combination treatment was
associated with non-statistically significant numerical
decreases in sweat chloride levels, along with a statis-
tically significant increase in FEV1 (+4.6 percentage
points, P = 0.012).
Future drug development of CFTR-targeted
therapies
Our understanding of the precise mechanism of action
of CFTR potentiators and correctors is increasing but
remains incomplete. This challenge partly reflects the
biological complexity of CFTR as a protein and the intri-
cacy of its interactions. The CFTR correctors lumacaftor
and VX-661 have been demonstrated to stabilize folding
defects between different domains of Phe508del-CFTR[76]. It is possible that future CFTR correctors will further
stabilize Phe508del-CFTR synergistically by targeting other
protein domains, thus allowing greater trafficking of CFTR
to the apical surface of cells [77, 78]. Increased knowledge
of the mechanisms of action of CFTR-modulating drugs,
along with the combination of more advanced and tract-
able experimental models, such as intestinal organoids
[79], primary airway epithelial cell cultures [80, 81] and the
application of genome editing technologies to stem cells
[82], with high-throughput screening technologies, are
likely to yield other small-molecule drugs for future treat-
ment of CFTR defects.
As mentioned earlier, almost 2000 individual CFTR
mutations have been identified, and particular challenges
exist around developing therapeutic strategies for CFTR
mutations that are individually very rare. These apply to
both basic drug discovery, where combined efforts to
generate biobanks of primary cells and tissues or use of
genetic techniques in cells to allow research in specific
mutations are likely to be necessary, and in demonstrat-
ing clinical efficacy. In the case of individually rare muta-
tions, ‘n-of-1’ level in vivo evidence of efficacy generated
by crossover studies may be important in assessing and
developing future CFTR modulation strategies and facili-
tating access to new drugs for patients [83].
The data from clinical trials of lumacaftor/ivacaftor and
VX-661/ivacaftor combination therapies support the con-
cept of the corrector/potentiator pharmacological ap-
proach in patients who are homozygous for the Phe508del
CFTR mutation, although further optimization of CFTR-
potentiating drugs is likely to be required to yield maximal
clinical benefits from combination therapy with ivacaftor.
There may also be the potential to use combination ther-
apy in patients who are heterozygous for Phe508del/
Gly551Asp CFTR mutations to build further on the
benefits associated with ivacaftor monotherapy.
Impact of targeted therapies on care
The introduction of ivacaftor as a mutation-specific treat-
ment that addresses the fundamental defect in people with
the Gly551Asp mutation has been hugely exciting for pa-
tients with cystic fibrosis and clinicians alike. It represents
one of the most powerful examples of precision medicine
to date. Improvements in lung function demonstrated in
RCTs, in conjunction with significant reductions in sweat
chloride levels, are without precedent in cystic fibrosis and
appear to be disease-modifying. The potential of small-
molecule drugs used in combination to modulate CFTR
function in other, much more prevalent mutations in the
cystic fibrosis population, most notably Phe508del, is real,
although the exact role and ‘real-life’ clinical efficacy of this
approach are still being debated and optimized. The pro-
spect of introducing CFTR-modulating therapies at a very
early stage of life, potentially in utero, and thereby limiting
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very attractive.
Optimism is appropriate but must be tempered
against experience and the realities of drug develop-
ment. Importantly, the longer-term benefits and effects
of CFTR-modulating treatment are yet to be completely
elucidated. Additionally, ivacaftor is an extremely ex-
pensive drug that costs in the region of US$300,000 an-
nually per patient. Cost–benefit analyses are fraught
with difficulty, because treatment would be lifelong by
definition, but may also be disease modifying and be as-
sociated with reductions in other treatment costs, as
well as potentially having wider societal benefits from
increasing the health of people with cystic fibrosis [84].
Ultimately, a new model of drug development may
evolve for orphan conditions such as cystic fibrosis, but
in the meantime such targeted treatments are more
expensive than previously accepted thresholds for
quality-adjusted life years [85]. The less substantial im-
provements in lung function demonstrated in the
TRAFFIC and TRANSPORT studies and approval of
ivacaftor/lumacaftor in 2015 by the FDA in the United
States are likely to generate further discussions about
the cost–benefit ratio associated with treatment [7].
Cystic fibrosis is a complex disease and it is well rec-
ognized that although the principals underlying the
genetic and functional defects in CFTR have been
identified, two individuals with the same CFTR geno-
type may follow a different natural history and trajec-
tory of their lung disease. The reason for this is
undoubtedly multifactorial, including environmental,
microbiological and socioeconomic factors, as well as
adherence with treatment, with modifier genes also
playing a role [86–89]. This heterogeneity adds a fur-
ther challenge in evaluating responses to new thera-
peutic interventions and may explain differences in
responses between individual patients. In this regard,
precision medicine arguably remains a relative term in
this area until our understanding increases. It is also
likely that heterogeneity between individuals extends
to the pharmacokinetics of CFTR-modulating drugs
and biomarker responses.
Conclusions
We have entered a new era of precision medicine in
cystic fibrosis. Such precise treatments offer huge po-
tential to target the underlying defects in specific
CFTR mutations and alter the disease process, and
could be life-changing. However, major challenges lie
ahead to demonstrate longer-term benefits of these
drugs, to develop compounds that target the most
common classes of CFTR mutations, and to establish
financially sustainable models of drug development
and delivery [90].Abbreviations
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